CN112641713A - 一种皮肤美容用复合因子试剂及其制备方法 - Google Patents
一种皮肤美容用复合因子试剂及其制备方法 Download PDFInfo
- Publication number
- CN112641713A CN112641713A CN202011607465.5A CN202011607465A CN112641713A CN 112641713 A CN112641713 A CN 112641713A CN 202011607465 A CN202011607465 A CN 202011607465A CN 112641713 A CN112641713 A CN 112641713A
- Authority
- CN
- China
- Prior art keywords
- cord blood
- umbilical cord
- stem cell
- skin
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 19
- 230000003796 beauty Effects 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 10
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 34
- 210000000130 stem cell Anatomy 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 14
- 239000003906 humectant Substances 0.000 claims abstract description 14
- 241000196324 Embryophyta Species 0.000 claims abstract description 13
- 210000002826 placenta Anatomy 0.000 claims abstract description 11
- 239000003102 growth factor Substances 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 239000006228 supernatant Substances 0.000 claims abstract description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 108010024636 Glutathione Proteins 0.000 claims abstract description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 7
- 240000000249 Morus alba Species 0.000 claims abstract description 7
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 7
- 230000010261 cell growth Effects 0.000 claims abstract description 7
- 229960003180 glutathione Drugs 0.000 claims abstract description 7
- 229960002897 heparin Drugs 0.000 claims abstract description 7
- 229920000669 heparin Polymers 0.000 claims abstract description 7
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 7
- 229940074410 trehalose Drugs 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000000341 volatile oil Substances 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 240000004371 Panax ginseng Species 0.000 claims description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000032696 parturition Effects 0.000 claims description 3
- 229940116257 pepper extract Drugs 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 2
- 241000222336 Ganoderma Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 23
- 239000000047 product Substances 0.000 abstract description 5
- 210000004927 skin cell Anatomy 0.000 abstract description 3
- 230000037394 skin elasticity Effects 0.000 abstract description 3
- 230000037303 wrinkles Effects 0.000 abstract description 3
- 208000032544 Cicatrix Diseases 0.000 abstract description 2
- 206010014970 Ephelides Diseases 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000003351 Melanosis Diseases 0.000 abstract description 2
- 239000013566 allergen Substances 0.000 abstract description 2
- 208000030961 allergic reaction Diseases 0.000 abstract description 2
- 230000019522 cellular metabolic process Effects 0.000 abstract description 2
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 238000004821 distillation Methods 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 231100000241 scar Toxicity 0.000 abstract description 2
- 230000037387 scars Effects 0.000 abstract description 2
- 230000002087 whitening effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及复合因子技术领域，且公开了一种皮肤美容用复合因子试剂，包括主要由以下物质按重量份数比制成的：脐带血干细胞活性物、胎盘活性物、复合细胞生长因子、海藻糖、肝素、谷胱甘肽、吸水类保湿剂、仿生类保湿剂、透皮组分、混合新鲜花瓣、薄荷叶、桑叶和混合植物干细胞活物；通过蒸馏盒得到纯露和精油，并通过离心机得到混合植物干细胞的上清液，将五种备用液按一定比例混合得到美容用复合因子试剂，该试剂对皮肤细胞具有良好的促进作用，可以加快细胞新陈代谢，具有除皱美白祛斑祛疤的功效，并能够保持皮肤弹性，恢复皮肤自然青青；同时，从根源上减少了生物制品中的过敏源，使得能够最大限度地降低使用人群对美容产品的过敏反应。
Description
技术领域
本发明涉及复合因子技术领域，具体为一种皮肤美容用复合因子试剂及其制备方法。
背景技术
复合因子就是多个功能或来源相关的因子的总称。如血小板类生长因子(血小板来源复合因子，PDGF；骨肉瘤来源复合因子ODGF)、表皮生长因子类(表皮生长因子，EGF、转化生长因子，TGFα和TGFβ)、成纤维细胞生长因子(αFGF、βFGF)、类胰岛素生长因子(IGF-Ⅰ、IGF-Ⅱ)、神经生长因子(NGF)、白细胞介素类生长因子(IL-1、IL-1、IL-3等)、红细胞生长素(EPO)、集落刺激因子(CSF)等，随年龄增长、紫外线的照射、环境的影响、疾病或者其他因素作用，皮肤逐渐受损衰老，主要表现为：角质化异常，角质层增厚或者减少、结构松散；表皮细胞数量减少，表皮细胞层厚度与角质层厚度均减少，皮肤的屏障保护功能变弱，保水功能降低，皮脂代谢变弱、油脂分泌减少；皮肤基底层中IV型胶原蛋白降解，基底层结构破坏，残余黑素细胞可能发生功能代偿性肥大，活力增强，导致皮肤有深浅不一的色素沉着；真皮厚度变薄、真皮细胞活力降低，弹力纤维、I型胶原蛋白均减少。外在表现为:皮肤干燥粗糙、缺乏滋润，色素小斑点脱失或沉着、老年斑皮脂分泌异常(增多或减少)，皮肤弹性降低，皮肤松她、粗糙，皱纹增多变深。
目前的护肤品采用的功效类的成分大多为化学合成所得，如烟酰胺、传明酸、苯乙基间苯二酚、对苯二酚等等，虽然这些成分可以提高皮肤的弹性，提高皮肤对水分的吸收能力以及锁水能力，但是这些合成的化学成分将会降低皮肤的耐受性，以及减弱皮肤自身的修复能力。
发明内容
(一)解决的技术问题
针对现有技术的不足，本发明提供了一种皮肤美容用复合因子试剂及其制备方法，具备天然植物提取的优点，解决了降低皮肤的耐受性的问题。
(二)技术方案
为实现上述目的，本发明提供如下技术方案：一种皮肤美容用复合因子试剂，包括主要由以下物质按重量份数比制成的：
脐带血干细胞活性物、胎盘活性物、复合细胞生长因子、海藻糖、肝素、谷胱甘肽、吸水类保湿剂、仿生类保湿剂、透皮组分、混合新鲜花瓣、薄荷叶、桑叶和混合植物干细胞活物。
优选的，所述透皮组分包括丙二醇、水溶性氮酮和/或胡椒提取物中的至少一种。
优选的，所述脐带血干细胞活性物和所述胎盘活性物均从牛分娩中提取。
优选的，包括以下步骤：
S1：混合新鲜花瓣、薄荷叶和桑叶，并通过蒸馏盒得到纯露和精油；
S2：将混合植物干细胞活物通过离心机破壁，去上层清液备用；
S3：将复合细胞生长因子、海藻糖、肝素、谷胱甘肽、吸水类保湿剂和仿生类保湿剂和透皮组分通过反应釜搅拌混合备用；
S4：提取脐带血保存，脐带血干细胞活性物提取备用；
S5：胎盘活性物质提取备用；
S6：将S1-S5中的备用液混合。
优选的，所述S2中的混合植物干细胞活物包括高丽参干细胞活物和灵芝干细胞活物。
优选的，所述S4中还包括以下步骤：
S41：取部分对应标号的脐带血水浴加热，将冷冻的脐带血缓慢解冻，从脐带血中提取血浆，使用血液分离机提取脐带血干细胞；
S42：健康检测，将脐带血干细胞接种在含有诱导因子的培养基中进行培养，诱导分化2天后检测细胞活性。
优选的，所述S4中还包括以下步骤：
S42：将诱导分化后细胞活性较差的脐带血从冷冻室内取出弃用，将细胞活性良好的脐带血继续放入冷冻室中保存。
优选的，所述S5还包括以下步骤：
S51：取新鲜胎盘用生理盐水反复漂洗，除尽淤血，绞碎，加甘油水溶液于低温下浸泡24小时，吊滤，取清液调pH值为4.5-5.5后，加0.5-12％明矾，静置过夜；
S52：取上清液，超滤，收集滤过部分，收集活性成分，再次过滤，收集滤过部分，用灭菌甘油水溶液稀释至浓度为20-50％，即成抽提液。
(三)有益效果
与现有技术相比，本发明提供了一种皮肤美容用复合因子试剂及其制备方法，具备以下有益效果：
该皮肤美容用复合因子试剂及其制备方法，通过蒸馏盒得到纯露和精油，并通过离心机得到混合植物干细胞的上清液，将五种备用液按一定比例混合得到美容用复合因子试剂，该试剂对皮肤细胞具有良好的促进作用，可以加快细胞新陈代谢，具有除皱美白祛斑祛疤的功效，并能够保持皮肤弹性，恢复皮肤自然青青；同时，从根源上减少了生物制品中的过敏源，使得能够最大限度地降低使用人群对美容产品的过敏反应。
附图说明
图1为本发明结构示意图。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
请参阅图1，一种皮肤美容用复合因子试剂，包括主要由以下物质按重量份数比制成的：
脐带血干细胞活性物、胎盘活性物、复合细胞生长因子、海藻糖、肝素、谷胱甘肽、吸水类保湿剂、仿生类保湿剂、透皮组分、混合新鲜花瓣、薄荷叶、桑叶和混合植物干细胞活物。
本实施例中，具体的，所述透皮组分包括丙二醇、水溶性氮酮和/或胡椒提取物中的至少一种。
本实施例中，具体的，所述脐带血干细胞活性物和所述胎盘活性物均从牛分娩中提取。
本实施例中，具体的，包括以下步骤：
S1：混合新鲜花瓣、薄荷叶和桑叶，并通过蒸馏盒得到纯露和精油；
S2：将混合植物干细胞活物通过离心机破壁，去上层清液备用；
S3：将复合细胞生长因子、海藻糖、肝素、谷胱甘肽、吸水类保湿剂和仿生类保湿剂和透皮组分通过反应釜搅拌混合备用；
S4：提取脐带血保存，脐带血干细胞活性物提取备用；
S5：胎盘活性物质提取备用；
S6：将S1-S5中的备用液混合。
本实施例中，具体的，所述S2中的混合植物干细胞活物包括高丽参干细胞活物和灵芝干细胞活物。
本实施例中，具体的，所述S4中还包括以下步骤：
S41：取部分对应标号的脐带血水浴加热，将冷冻的脐带血缓慢解冻，从脐带血中提取血浆，使用血液分离机提取脐带血干细胞；
S42：健康检测，将脐带血干细胞接种在含有诱导因子的培养基中进行培养，诱导分化2天后检测细胞活性。
本实施例中，具体的，所述S4中还包括以下步骤：
S42：将诱导分化后细胞活性较差的脐带血从冷冻室内取出弃用，将细胞活性良好的脐带血继续放入冷冻室中保存。
本实施例中，具体的，所述S5还包括以下步骤：
S51：取新鲜胎盘用生理盐水反复漂洗，除尽淤血，绞碎，加甘油水溶液于低温下浸泡24小时，吊滤，取清液调pH值为4.5-5.5后，加0.5-12％明矾，静置过夜；
S52：取上清液，超滤，收集滤过部分，收集活性成分，再次过滤，收集滤过部分，用灭菌甘油水溶液稀释至浓度为20-50％，即成抽提液。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (8)
1.一种皮肤美容用复合因子试剂，其特征在于：包括主要由以下物质按重量份数比制成的：
脐带血干细胞活性物、胎盘活性物、复合细胞生长因子、海藻糖、肝素、谷胱甘肽、吸水类保湿剂、仿生类保湿剂、透皮组分、混合新鲜花瓣、薄荷叶、桑叶和混合植物干细胞活物。
2.根据权利要求1所述的一种皮肤美容用复合因子试剂，其特征在于：所述透皮组分包括丙二醇、水溶性氮酮和/或胡椒提取物中的至少一种。
3.根据权利要求1所述的一种皮肤美容用复合因子，其特征在于：所述脐带血干细胞活性物和所述胎盘活性物均从牛分娩中提取。
4.一种皮肤美容用复合因子试剂制备方法，根据权利要求1-3所述的一种皮肤美容用复合因子试剂，其特征在于：包括以下步骤：
S1：混合新鲜花瓣、薄荷叶和桑叶，并通过蒸馏盒得到纯露和精油；
S2：将混合植物干细胞活物通过离心机破壁，去上层清液备用；
S3：将复合细胞生长因子、海藻糖、肝素、谷胱甘肽、吸水类保湿剂和仿生类保湿剂和透皮组分通过反应釜搅拌混合备用；
S4：提取脐带血保存，脐带血干细胞活性物提取备用；
S5：胎盘活性物质提取备用；
S6：将S1-S5中的备用液混合。
5.根据权利要求4所述的一种皮肤美容用复合因子试剂及其制备方法，其特征在于：所述S2中的混合植物干细胞活物包括高丽参干细胞活物和灵芝干细胞活物。
6.根据权利要求4所述的一种皮肤美容用复合因子试剂及其制备方法，其特征在于：所述S4中还包括以下步骤：
S41：取部分对应标号的脐带血水浴加热，将冷冻的脐带血缓慢解冻，从脐带血中提取血浆，使用血液分离机提取脐带血干细胞；
S42：健康检测，将脐带血干细胞接种在含有诱导因子的培养基中进行培养，诱导分化2天后检测细胞活性。
7.根据权利要求6所述的一种皮肤美容用复合因子试剂及其制备方法，其特征在于：所述S4中还包括以下步骤：
S42：将诱导分化后细胞活性较差的脐带血从冷冻室内取出弃用，将细胞活性良好的脐带血继续放入冷冻室中保存。
8.根据权利要求7所述的一种皮肤美容用复合因子试剂及其制备方法，其特征在于：所述S5还包括以下步骤：
S51：取新鲜胎盘用生理盐水反复漂洗，除尽淤血，绞碎，加甘油水溶液于低温下浸泡24小时，吊滤，取清液调pH值为4.5-5.5后，加0.5-12％明矾，静置过夜；
S52：取上清液，超滤，收集滤过部分，收集活性成分，再次过滤，收集滤过部分，用灭菌甘油水溶液稀释至浓度为20-50％，即成抽提液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011607465.5A CN112641713A (zh) | 2020-12-30 | 2020-12-30 | 一种皮肤美容用复合因子试剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011607465.5A CN112641713A (zh) | 2020-12-30 | 2020-12-30 | 一种皮肤美容用复合因子试剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112641713A true CN112641713A (zh) | 2021-04-13 |
Family
ID=75364056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011607465.5A Pending CN112641713A (zh) | 2020-12-30 | 2020-12-30 | 一种皮肤美容用复合因子试剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112641713A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008038148A2 (en) * | 2006-05-11 | 2008-04-03 | Andrew Craig Boquest | Stem cells and methods of making and using stem cells |
| CN102552099A (zh) * | 2011-12-30 | 2012-07-11 | 王英丽 | 一种用于皮肤美容修复的复合生物制剂及制备方法 |
| CN106691923A (zh) * | 2016-12-12 | 2017-05-24 | 上海先妍生物技术有限公司 | 用于美容修复的组合物和制剂及其制备方法和应用 |
| CN111632020A (zh) * | 2020-07-09 | 2020-09-08 | 刘赛 | 一种干细胞复合因子抗衰老保湿化妆品 |
-
2020
- 2020-12-30 CN CN202011607465.5A patent/CN112641713A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008038148A2 (en) * | 2006-05-11 | 2008-04-03 | Andrew Craig Boquest | Stem cells and methods of making and using stem cells |
| CN102552099A (zh) * | 2011-12-30 | 2012-07-11 | 王英丽 | 一种用于皮肤美容修复的复合生物制剂及制备方法 |
| CN106691923A (zh) * | 2016-12-12 | 2017-05-24 | 上海先妍生物技术有限公司 | 用于美容修复的组合物和制剂及其制备方法和应用 |
| CN111632020A (zh) * | 2020-07-09 | 2020-09-08 | 刘赛 | 一种干细胞复合因子抗衰老保湿化妆品 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108186548A (zh) | 一种具有抗衰老效果的干细胞因子精华液的制备方法 | |
| CN111317701B (zh) | 一种皮肤屏障修护复合物、护肤乳液及其制备方法 | |
| CN109010245B (zh) | 祛痘制剂 | |
| CN111821252A (zh) | 一种含脂肪干细胞提取物的抗皱精华液及其制备方法 | |
| CN106967679B (zh) | 一种高浓度葡萄糖溶液激活的间充质干细胞条件培养基的制备方法及其应用 | |
| CN104288129A (zh) | 一种用于抗皱祛斑的干细胞微针贴片及其制备方法 | |
| CN113041206A (zh) | 一种含间充质干细胞因子的精华液及其制备方法 | |
| CN111973647B (zh) | 金银花发酵物的制备方法及其改善皮肤外观与抗老化的用途 | |
| CN114344188A (zh) | 一种防脱育发组合物及其制备方法 | |
| CN111690600A (zh) | 一种工程化人脐带间充质干细胞外泌体及透皮制剂与应用 | |
| CN102233144A (zh) | 一种利用组织工程技术进行皮下组织再生的方法 | |
| CN111012700A (zh) | 凉薯发酵物及其用于制备提升基因表现量、以及降低皮肤黑色素含量的组合物的用途 | |
| CN111803395A (zh) | 自体胶原修复营养注射液及其制备方法 | |
| CN108096138A (zh) | 一种抗衰老皮肤修复液及其制备方法 | |
| CN113712893A (zh) | 一种用于化妆品脐带间充质干细胞提取物的制备方法 | |
| CN112641713A (zh) | 一种皮肤美容用复合因子试剂及其制备方法 | |
| CN111759762A (zh) | 祛黑眼圈组合物、精华及其制备方法 | |
| CN108186438A (zh) | 一种含有细胞生长因子的晒后修复凝胶及其制备方法 | |
| CN111544352B (zh) | 银耳-灵芝复合发酵物、具有抗衰老功效的化妆品用组合物及其制备方法和应用 | |
| CN113197920A (zh) | 一种皮肤抗衰老用胚胎干细胞培养提取物的制备方法 | |
| CN113476362B (zh) | 一种面部皮肤角质更新促进剂及其应用 | |
| CN112852724A (zh) | 一种含干细胞活性因子的美容组合物及其制备方法和应用 | |
| CN112618468A (zh) | 一种高效抗糖精华液及其制备方法 | |
| CN110934815A (zh) | 一种含有间充质干细胞培养上清液的抗糖化面膜及其制备方法 | |
| CN117243885B (zh) | 一种改善皮肤的干细胞外泌体组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210413 |
|
| RJ01 | Rejection of invention patent application after publication |